TrialNature medicine2024

Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial.

Thomas Powles et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.